{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:39:58Z","timestamp":1767706798093,"version":"3.44.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.ad.2015.01.010","type":"journal-article","created":{"date-parts":[[2015,3,14]],"date-time":"2015-03-14T00:48:34Z","timestamp":1426294114000},"page":"477-482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Riesgo de reactivaci\u00f3n de hepatitis B pasada en pacientes con psoriasis tratados con biol\u00f3gicos. An\u00e1lisis retrospectivo de 20 casos. Registro de BIOBADADERM"],"prefix":"10.1016","volume":"106","author":[{"given":"J.","family":"Sanz-Bueno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Vanaclocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Garc\u00eda-Doval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Torrado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Carretero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Daud\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Patricia Ruiz-Genao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.M.","family":"Alsina-Gibert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"P\u00e9rez-Zafrilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"P\u00e9rez-Rial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2015.01.010_bib0160","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S0168-8278(03)00141-7","article-title":"Epidemiology of hepatitis B in Europe and worldwide","volume":"39","author":"Alter","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2015.01.010_bib0165","doi-asserted-by":"crossref","first-page":"8726","DOI":"10.1016\/j.vaccine.2007.10.027","article-title":"Declining prevalence of hepatitis B virus infection in Catalonia (Spain) 12 years after the introduction of universal vaccination","volume":"25","author":"Salleras","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ad.2015.01.010_bib0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2015.01.010_bib0175","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: Epidemiology, clinical features, and quality of life","volume":"64 Suppl 2","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2015.01.010_bib0180","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ad.2013.12.008","article-title":"Prevalencia de la psoriasis en Espa\u00f1a en la era de los agentes biol\u00f3gicos","volume":"105","author":"Ferr\u00e1ndiz","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2015.01.010_bib0185","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1365-2133.2008.08851.x","article-title":"The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: A review of the literature","volume":"159","author":"Domm","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2015.01.010_bib0190","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ad.2010.10.016","article-title":"BIOBADADERM, the Spanish registry of adverse events associated with biologic drugs in dermatology: First report","volume":"102","author":"Rivera","year":"2011","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2015.01.010_bib0195","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/0016-5085(87)90613-5","article-title":"Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection","volume":"92","author":"Lok","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ad.2015.01.010_bib0200","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/jama.1983.03330370053031","article-title":"If nothing goes wrong, is everything all right? Interpreting zero numerators","volume":"249","author":"Hanley","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.ad.2015.01.010_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J Eur Acad DermatolVenereol"},{"key":"10.1016\/j.ad.2015.01.010_bib0210","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archdermatol.2011.1410","article-title":"Consensus guidelines for the management of plaque psoriasis","volume":"148","author":"Hsu","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2015.01.010_bib0215","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2007.10.011","article-title":"Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection","volume":"38","author":"Carroll","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ad.2015.01.010_bib0220","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: Analysis of 257 patients","volume":"90","author":"P\u00e9rez-Alvarez","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ad.2015.01.010_bib0225","first-page":"118","article-title":"Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy","volume":"31","author":"Lee","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ad.2015.01.010_bib0230","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1157\/13087150","article-title":"Reactivation of hepatitis B treated with adefovir after infliximab administration","volume":"126","author":"N\u00fa\u00f1ez-Rodr\u00edguez","year":"2006","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.ad.2015.01.010_bib0235","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jaad.2008.09.057","article-title":"Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection","volume":"60","author":"Conde-Taboada","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2015.01.010_bib0240","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1365-2133.2010.09714.x","article-title":"Safety of antitumour necrosis factor-\u03b1 therapy in psoriatic patients with hepatitis B virus infection","volume":"162","author":"Nosotti","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2015.01.010_bib0245","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1346-8138.2011.01434.x","article-title":"Use of anti-tumor necrosis factor-\u03b1 therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan","volume":"39","author":"Cho","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2015.01.010_bib0250","first-page":"285","article-title":"Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease","volume":"25","author":"Cassano","year":"2011","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.ad.2015.01.010_bib0255","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1468-3083.2010.03754.x","article-title":"Safety of anti-tumour necrosis factor-alpha agents in psoriasis patients who were chronic hepatitis B carriers: A retrospective report of seven patients and brief review of the literature","volume":"25","author":"Fotiadou","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2015.01.010_bib0260","first-page":"23","article-title":"Hepatitis-B reactivation during treatment with tumor necrosis factor-\u03b1 blocker adalimumab in a patient with psoriasis arthritis","volume":"137","author":"Kouba","year":"2012","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.ad.2015.01.010_bib0265","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.12045","article-title":"Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: A retrospective, multicentre study in a clinical setting","volume":"168","author":"Navarro","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2015.01.010_bib0270","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jaad.2012.04.036","article-title":"Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management","volume":"67","author":"Abramson","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2015.01.010_bib0275","first-page":"645","article-title":"Tumour necrosis factor-\u03b1 antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: A retrospective analysis of 17 patients","volume":"164","author":"Prignano","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2015.01.010_bib0280","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/ijd.12313","article-title":"Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis","volume":"53","author":"Navarro","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2015.01.010_bib0285","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cellimm.2011.10.016","article-title":"Serum levels of interleukin-12 in various clinical states with hepatitis B virus infection","volume":"272","author":"He","year":"2012","journal-title":"Cell Immunol"},{"key":"10.1016\/j.ad.2015.01.010_bib0290","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjd.12120","article-title":"Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient","volume":"168","author":"Koskinas","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2015.01.010_bib0295","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"Chiu","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2015.01.010_bib0300","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1136\/ard.2010.148783","article-title":"Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy","volume":"70","author":"Lan","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2015.01.010_bib0305","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/gut.2010.208413","article-title":"Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy","volume":"59","author":"Loras","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.ad.2015.01.010_bib0310","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00535-010-0367-5","article-title":"Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: Evaluation of both HBsAg-positive and HBsAg-negative cohorts","volume":"46","author":"Tamori","year":"2011","journal-title":"J Gastroenterol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731015000733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731015000733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:03:33Z","timestamp":1757552613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731015000733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0001731015000733"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2015.01.010","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Riesgo de reactivaci\u00f3n de hepatitis B pasada en pacientes con psoriasis tratados con biol\u00f3gicos. An\u00e1lisis retrospectivo de 20 casos. Registro de BIOBADADERM","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2015.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. and AEDV. All rights reserved.","name":"copyright","label":"Copyright"}]}}